Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The Company develops immunotherapies based on cutting-edge Toll-Like Receptor biology and its ability to modulate the immune system.Dynavax Technologies Corporation's clinical-stage product candidates include HBsAg-1018 is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response designed to provide protection against hepatitis B; and the Company's lead cancer immunotherapy compound, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells to antigen-presenting cells.